We develop macrophage-targeted LNPs through macrophage-tropic lipid design and surface ligand functionalization, providing end-to-end support from ligand selection and lipid synthesis to formulation, characterization, and delivery evaluation.
Macrophage-targeted LNPs are engineered to deliver nucleic acid and other payloads into macrophage populations with functional outcomes, rather than being passively cleared by them. Conventional LNPs are rapidly captured by the mononuclear phagocyte system and accumulate mainly in liver and spleen, where Kupffer cells and splenic red pulp macrophages take up particles efficiently but often without productive payload expression. Macrophage-targeted formulations counter this default behavior by combining receptor-directed ligands such as mannose, galactose derivatives, antibodies, and macrophage-subset peptides with lipid-intrinsic engineering approaches, including selective organ targeting (SORT) compositions and phosphatidylserine-based biomimetic designs.
BOC Sciences provides integrated targeted LNP development, covering targeting ligand synthesis and conjugation, ionizable and helper lipid screening, payload encapsulation, formulation optimization, and cellular and in vivo evaluation. We support macrophage-directed delivery of mRNA, siRNA, miRNA, plasmid DNA, and genome-editing payloads across liver, spleen, lung, tumor, and plaque macrophage contexts, with the development scope adapted to the intended cell population and biological endpoint.
Macrophage-Targeted Lipid Nanoparticle IllustrationMacrophage-targeted LNPs are lipid nanoparticles designed so that a defined macrophage population takes them up preferentially and productively. Targeting is achieved through two complementary layers. The first is surface ligand recognition: ligands displayed on the LNP surface bind receptors that are abundant or activation-specific on macrophages, triggering receptor-mediated endocytosis. The second is lipid-intrinsic and biomimetic targeting: particle composition is tuned so that the adsorbed protein corona or the particle surface itself mimics natural macrophage ligands, redirecting biodistribution toward macrophage-rich compartments.
Because macrophages are highly heterogeneous, the choice of targeting mechanism must match the intended cell population. The table below summarizes receptor–ligand pairs commonly used to direct LNPs to macrophages:
| Macrophage Receptor | Ligand or Design Feature | Macrophage-Targeting Relevance |
|---|---|---|
| Mannose receptor (CD206/MRC1) | Mannose or mannosylated PEG-lipids | Highly expressed on alternatively activated (M2-like) macrophages, including profibrotic lung macrophages, SPP1+ tumor-associated macrophages, and Kupffer cells. |
| C-type lectin receptors (MGL1/2, Dectin-1) | Galactose and glycolipid structures | Recognized on macrophage galactose-type lectins and pattern-recognition receptors, enabling subset-selective glycan targeting. |
| Scavenger receptors (SR-A, MARCO, Stabilin-2) | Anionic or polyanionic surfaces, S2P peptide | Mediate uptake of anionic particles and peptide-targeted LNPs by plaque macrophages and splenic macrophages. |
| Tim-4 and MerTK | Phosphatidylserine on the particle surface | Mimics the "eat-me" signal of apoptotic bodies, driving selective uptake by phagocytic macrophages. |
| Folate receptor-β (FR-β) | Folate ligands | Upregulated on activated macrophages in inflammatory and autoimmune contexts. |
| Corona-mediated recognition (β2-GPI, ApoE) | Anionic SORT lipids, lipid headgroup tuning | Shapes the protein corona so that spleen CD169+ red pulp macrophages or other macrophage compartments preferentially capture the particles. |
BOC Sciences develops macrophage-targeted LNPs by matching these recognition mechanisms to the payload, the tissue environment, and the required functional readout, so that uptake translates into measurable gene silencing, protein expression, or cell-state modulation rather than simple particle clearance.
Our development services integrate lipid chemistry, ligand engineering, nanoparticle formulation, and biological evaluation to address the specific challenges of macrophage delivery. Projects can start with an existing LNP formulation, a candidate targeting ligand, or only a defined macrophage-delivery objective. We customize the development scope according to payload properties, target-cell characteristics, and the intended administration route.
We investigate how ionizable lipid structures and supporting lipid components influence macrophage interactions, intracellular delivery, and biodistribution toward macrophage-rich organs.
We develop ligand-functionalized LNPs that engage macrophage receptors with controlled density and accessibility. Ligand identity, attachment chemistry, spacer design, and surface display are optimized together.
We integrate lipid composition, targeting modifications, and payload properties into a formulation strategy designed for the intended macrophage-delivery application.
We evaluate the physicochemical properties of candidate LNPs alongside macrophage-cell delivery and tissue-level performance to identify whether formulation improvements translate into functional payload delivery.
Macrophage-targeted LNPs can be developed through receptor-mediated ligand recognition, biomimetic surface engineering, or intrinsic lipid composition modification. The selection of a targeting strategy depends on macrophage subtype, receptor expression, administration route, and payload requirements. BOC Sciences supports the development and comparative evaluation of the following approaches.
Glycan-functionalized LNPs use carbohydrate ligands to interact with lectin receptors expressed by selected macrophage populations. Mannose is particularly relevant to CD206-mediated uptake, whereas galactose can interact with macrophage galactose-type lectin CD301. The targeting outcome depends on receptor abundance, ligand presentation, and the distribution of these receptors across different tissue cells.
Research reference: Mannose-conjugated cholesterol LNPs for Kupffer cell delivery (Bioconjugate Chemistry, 2025); mannosylated spleen-targeted mRNA-LNPs for macrophage-associated delivery (ACS Biomaterials Science & Engineering, 2026).
Antibody-functionalized LNPs use surface-displayed antibodies or antibody fragments to recognize selected macrophage-associated membrane proteins. This approach can provide an additional recognition layer beyond the natural phagocytic uptake of conventional LNPs, making it useful when a defined cell-surface marker is available.
Research reference: A study screened 112 LNP formulations and subsequently conjugated an F4/80 antibody to the selected LNP surface for macrophage-targeted TAK1 siRNA delivery in a viral pneumonia model (Proceedings of the National Academy of Sciences, 2024).
Peptide-functionalized LNPs use short recognition sequences or cell-penetrating peptides to improve interactions with selected macrophage populations. Peptides can be attached to lipid anchors or PEG-lipid conjugates, providing a flexible surface architecture for investigating macrophage-subset recognition and intracellular delivery.
Research reference: M2 macrophage-targeting peptide-modified liposomes were investigated for enhanced uptake and antitumor activity of liposomal IFN-γ in a murine tumor model (Cytokine, 2025). This provides supporting evidence for peptide-mediated macrophage recognition in lipid vesicles; direct performance in conventional LNP formulations requires independent evaluation.
Lipid-intrinsic targeting modifies the composition and physicochemical characteristics of LNPs to influence organ distribution and interactions with phagocytic cells. Biomimetic designs can incorporate phosphatidylserine (PS), a natural membrane lipid associated with apoptotic-cell recognition, to promote interactions with phagocytes.
Research reference: PS-containing LNPs promoted monocyte/macrophage-mediated mRNA delivery to secondary lymphoid organs (Nano Letters, 2022); SORT-LNPs enabled composition-dependent tissue targeting for mRNA delivery and CRISPR-Cas gene editing (Nature Nanotechnology, 2020).
Share your target macrophage population, receptor information, payload, and intended administration route. BOC Sciences can help compare ligand-mediated, antibody-based, peptide-functionalized, and lipid-intrinsic targeting approaches to identify suitable development options.
Macrophage-targeted LNPs have been investigated for different payload classes, particularly nucleic acids used to regulate macrophage gene expression, protein production, and functional states. BOC Sciences supports payload-specific formulation and encapsulation strategies, with the development approach selected according to cargo chemistry, intracellular destination, and desired biological response.
| Payload Type | Supported Uses & Macrophage-Targeted LNP Development Considerations | Request Information |
|---|---|---|
| Macrophage-Targeted LNP for mRNA | Designed for transient expression of transcription factors, immune-modulating proteins, cytokines, and chimeric antigen receptors (CARs) in macrophages. Applications include macrophage reprogramming, tumor microenvironment modulation, and protein-expression research. Development focuses on mRNA integrity, encapsulation, intracellular release, and cell-specific protein expression. Recent studies have investigated mannose-functionalized LNPs and macrophage-targeted mRNA delivery for in situ CAR-macrophage programming. Supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| Macrophage-Targeted LNP for siRNA | Suitable for silencing macrophage-associated inflammatory and immunoregulatory genes. Published research has investigated siRNA against TAK1, c-Rel, IRF5, and SHP-1 in macrophage-related delivery systems. Development emphasizes cytosolic siRNA availability, target-gene knockdown, macrophage-subset selectivity, and functional changes in inflammatory signaling. Our lipid nanoparticles for siRNA delivery services support customized formulations and gene-silencing evaluation. | Inquiry |
| Macrophage-Targeted LNP for CRISPR Components | Can be explored for targeted genome-editing research using Cas9 mRNA with guide RNA or Cas9 ribonucleoprotein (RNP) payloads. Formulation development considers co-encapsulation, cargo stoichiometry, RNA integrity, intracellular release, and editing activity in the intended macrophage population. Macrophage-specific editing requires direct validation rather than relying solely on organ-level delivery results. Our lipid nanoparticles for CRISPR RNP delivery services support related nucleic acid delivery development. | Inquiry |
| Macrophage-Targeted LNP for Immunomodulatory Co-Delivery | Designed for selected combinations of RNA payloads and immunomodulatory compounds. For example, macrophage-targeted mRNA-LNP research has explored combining CAR-encoding mRNA with an immune agonist to support macrophage programming. Development focuses on compatibility between lipid components and each payload, loading sequence, release behavior, and preservation of functional activity. Our LNP co-delivery services support the evaluation of multiple-payload formulations. | Inquiry |
| Macrophage-Targeted LNP for Custom Payloads | Developed for other nucleic acids, selected hydrophobic compounds, or specialized payload combinations. We assess lipid-payload compatibility, encapsulation or incorporation methods, surface modification compatibility, payload retention, and macrophage-associated delivery performance. For hydrophobic cargo, our hydrophobic payload encapsulation in LNPs capabilities can support formulation development. | Inquiry |
Tell us your payload, target macrophage population, and desired biological outcome. BOC Sciences can help select suitable lipid components, targeting ligands, and formulation conditions for your project.
Projects can begin with an existing LNP formulation, a candidate macrophage-targeting ligand, or a defined cell-specific delivery objective. We organize the development process into four practical stages and refine the formulation according to physicochemical and biological evaluation results.

We review the target tissue, macrophage population, species, receptor expression profile, payload class, and intended biological response. The target may be tumor-associated macrophages, Kupffer cells, alveolar macrophages, splenic macrophages, or activated inflammatory macrophages. These inputs determine the appropriate cellular models, candidate targeting ligands, and functional evaluation endpoints.

We propose candidate ionizable lipids, helper phospholipids, cholesterol, and PEG-lipid components, then compare suitable targeting architectures such as mannose, antibodies, peptides, PS-containing lipids, or SORT-based compositions. Ligand density, PEG shielding, and lipid ratios are optimized through structured LNP lipid ratio optimization services. Matched non-targeted LNPs are included to distinguish the contribution of the targeting modification from the intrinsic uptake of the carrier.

Candidates are prepared using selected mixing and formulation conditions and compared for particle size, PDI, zeta potential, morphology, ligand presentation, and payload retention. We refine lipid composition, mixing parameters, purification, and buffer exchange during formulation development. Additional nanoparticle intracellular localization detection can help investigate particle trafficking and payload distribution after cellular uptake.

Selected formulations are evaluated in macrophage models using fluorescence imaging, flow cytometry, and payload-specific endpoints such as reporter expression, protein production, or gene knockdown. Nanoparticle in vivo distribution analysis can further compare tissue accumulation, macrophage localization, and off-target organ exposure. The resulting data support candidate ranking and the next formulation optimization cycle.
Macrophage-targeted LNPs must overcome several interconnected delivery barriers. A formulation may show strong particle uptake but insufficient functional payload expression, or accumulate in a target organ without reaching the intended macrophage population. We investigate lipid composition, ligand accessibility, macrophage biology, and intracellular delivery together to identify the factors limiting performance.
✔ Insufficient Macrophage-Targeted LNP Delivery and Off-Target Uptake
Conventional LNPs can undergo extensive hepatic uptake and interact with multiple phagocytic populations after systemic administration. Consequently, high total particle accumulation does not necessarily indicate efficient delivery to the intended macrophages. We compare ionizable lipid structures, helper lipid compositions, surface charge, PEG-lipid content, and targeting ligands to investigate these distribution patterns. Candidate formulations are evaluated using target-to-off-target cell uptake and functional expression measurements rather than relying only on total organ fluorescence.
✔ Variable LNP Uptake Across Macrophage Subsets and Activation States
Macrophage populations differ in receptor abundance, phagocytic activity, membrane composition, and intracellular trafficking. For example, CD206 expression can vary between tissue-resident macrophages and activated macrophage populations, while the commonly used M1/M2 classification does not fully represent the diversity of macrophage states in tissues. We select relevant macrophage models, compare receptor expression, and investigate ligand-dependent uptake across different cellular conditions. This helps identify whether a targeting strategy is suitable for the intended macrophage population rather than macrophages in general.
✔ PEG Shielding, Ligand Accessibility, and LNP Stability
PEG-lipids help maintain colloidal stability and influence interactions between LNPs and biological environments, but excessive surface shielding can reduce ligand accessibility and receptor recognition. Conversely, insufficient PEG coverage may affect particle stability and increase nonspecific interactions. We optimize PEG-lipid content, hydrophobic anchor structure, ligand spacer length, and surface density together. A 2026 HA-functionalized LNP study demonstrated that a formulation with 0.5% PEG-lipid showed improved uptake in activated macrophages compared with a 1.5% PEG-lipid formulation, illustrating the importance of balancing surface stabilization and ligand accessibility. Our LNP PEG-lipid optimization services support this type of formulation investigation.
✔ Limited Endosomal Escape and Payload Release from LNPs
Macrophages can internalize substantial amounts of nanoparticles through phagocytic and endocytic pathways, but internalization alone does not guarantee cytosolic payload availability. LNPs may remain trapped in endosomal or lysosomal compartments, resulting in limited mRNA translation or siRNA-mediated gene silencing. We investigate ionizable lipid pKa, helper lipid composition, membrane interactions, and intracellular trafficking to identify post-uptake limitations. Functional reporter expression, gene knockdown, and intracellular localization are evaluated together through our LNP endosomal escape evaluation services.
Tell us about your current lipid composition, targeting ligand, macrophage model, and delivery results. BOC Sciences can help investigate uptake limitations, ligand accessibility, particle stability, and intracellular payload release to establish a focused optimization strategy.
Macrophages participate in tumor progression, inflammatory signaling, tissue repair, pathogen clearance, and lipid metabolism. Their ability to internalize nanoparticles makes them important targets for nucleic acid delivery and cellular reprogramming research. BOC Sciences supports customized LNP development for the following application areas, including targeting ligand selection, payload formulation, and functional delivery evaluation.
Research reference: In situ programming of tailored CAR macrophages using mRNA-LNPs (Nature Communications, 2026).
Research reference: DSPS-containing lipid nanoparticles for c-Rel siRNA delivery to immune cells (PLOS ONE, 2022); HA-functionalized LNPs for activated macrophage mRNA delivery (Biomacromolecules, 2026).
Research reference: F4/80-antibody-functionalized LNPs were developed for macrophage-targeted TAK1 siRNA delivery in a viral pneumonia model, with reported improvements in macrophage targeting and pulmonary inflammatory outcomes (Proceedings of the National Academy of Sciences, 2024).
Research reference: Mannose-modified LNPs carrying SHP-1 siRNA were investigated for delivery to macrophages in atherosclerotic vulnerable plaques. In a mouse model, the piperazine-structured formulation achieved a reported M2 macrophage uptake efficiency of 46.32% (Nano Letters, 2026).
Tell us your target macrophage population, tissue of interest, payload, and development requirements. BOC Sciences can help design, synthesize, formulate, and evaluate macrophage-targeted LNPs using suitable lipid and ligand engineering strategies.
We connect macrophage receptor profiles, lipid composition, and ligand presentation to cellular delivery outcomes. Our development approach considers the differences between tissue-resident macrophages, activated inflammatory macrophages, and tumor-associated macrophages to support target-specific formulation design.

In addition to customized development services, BOC Sciences provides LNP-related lipid raw materials and formulation components, including ionizable lipids, helper phospholipids, PEG-lipids, cholesterol-based components, and functional lipid materials. We help select suitable starting materials according to payload chemistry, targeting architecture, and formulation requirements, supporting projects that need both raw material supply and customized LNP development.
Our capabilities cover lipid modification, ligand-lipid conjugate synthesis, antibody and peptide coupling, and carbohydrate functionalization. Through customized nanoparticle surface functionalization services and custom synthesis, we support the development of targeting components matched to specific macrophage populations.
Particle characterization, macrophage uptake analysis, intracellular localization, functional payload expression, and in vivo distribution can be incorporated into one development program. Our nanoparticle in vitro evaluation capabilities help connect formulation properties with cellular performance.
From lipid and ligand selection to formulation, process optimization, characterization, and delivery evaluation, we organize the development workflow around your target macrophage population and payload requirements. Our LNP lipid library screening services support comparative candidate selection and iterative formulation development.
Macrophage-targeted lipid nanoparticles (LNPs) are lipid-based delivery systems engineered to transport nucleic acids or other bioactive payloads preferentially into selected macrophage populations within specific tissues. Their targeting properties can be achieved through surface-functionalized ligands, such as mannose, antibodies, or peptides that recognize macrophage-associated receptors, or through lipid composition modifications that influence cellular interactions, protein-corona formation, and tissue distribution. Some formulations also incorporate biomimetic lipids, such as phosphatidylserine, to promote phagocyte recognition and uptake. Because macrophages differ in receptor expression and activation states, successful development requires evaluating both cell-specific uptake and functional payload delivery rather than relying solely on particle accumulation.
Several ligand types can be incorporated into LNP surfaces to improve interactions with selected macrophage populations. Mannose is commonly investigated for CD206-mediated recognition, while galactose-containing structures can interact with CD301-expressing cells. Antibodies against markers such as F4/80 in murine models, CD163, or CD206 provide additional receptor-recognition options. Folate and macrophage-binding peptides are also investigated for selected macrophage populations. Ligand selection should consider receptor abundance, species differences, and expression on non-target cells. BOC Sciences supports ligand synthesis, lipid conjugation, surface functionalization, and comparative evaluation of targeting architectures.
Macrophage-targeted LNPs are particularly suitable for delivering nucleic acid payloads, including mRNA, siRNA, and CRISPR-associated components. mRNA can support transient expression of immune-modulating proteins or cellular engineering factors, whereas siRNA can silence genes involved in inflammatory signaling, macrophage activation, and tumor-associated immunosuppression. Co-delivery of different RNA payloads can also be investigated when multiple biological pathways need to be modulated. For example, TAM-targeted LNP research has explored STAT3 and HIF-1α silencing, as well as mRNA-mediated macrophage reprogramming. BOC Sciences provides payload-compatible LNP formulation, encapsulation optimization, and functional delivery evaluation.
Evaluation should distinguish particle uptake, intracellular payload delivery, and functional biological activity. Physicochemical characterization includes particle size, PDI, zeta potential, morphology, and encapsulation efficiency. Cellular studies can compare LNP uptake across selected macrophage populations and other immune cells using fluorescence imaging and flow cytometry. Functional evaluation may include reporter expression, target-gene knockdown, and changes in macrophage-associated signaling. For studies, tissue distribution should be combined with cell-specific localization to determine whether LNPs reach the intended macrophage population. BOC Sciences integrates nanoparticle characterization, cellular uptake testing, and delivery evaluation.
Several factors can limit macrophage-targeted LNP performance. Off-target uptake by the liver, spleen, and other phagocytic cells may reduce delivery to the intended population. Macrophage heterogeneity and variable receptor expression can also cause inconsistent targeting across tissues and activation states. Furthermore, protein-corona formation may mask surface ligands, while excessive PEG-lipid content can reduce receptor accessibility. Even after cellular internalization, limited endosomal escape may prevent RNA payloads from reaching the cytosol. Addressing these challenges requires coordinated optimization of lipid composition, ligand density, particle stability, and intracellular delivery properties.